키닉사 파마슈티컬스 인터내셔널 주식회사

SecurityKNSA / Kiniksa Pharmaceuticals International, plc
InstitutionJanus Henderson Group Plc
Latest Disclosed Ownership481,023 shares
Latest Disclosed Value $ 23,197,334
Janus Henderson Group Plc reports 213.52% increase in ownership of KNSA / Kiniksa Pharmaceuticals International, plc

On May 18, 2026 - Janus Henderson Group Plc filed a 13F-HR/A form disclosing ownership of 481,023 shares of Kiniksa Pharmaceuticals International, plc (US:KNSA) valued at $23,161,257 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 153,428 shares of Kiniksa Pharmaceuticals International, plc. This represents a change in shares of 213.52% during the quarter. The current value of the position is $23,291,134 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-18 2026-03-31 13F/A-1 KINIKSA PHARMACEUTICALS INTL ORD SHS CL A G52694109 481,023 327,595 213.52 23,197 266.75 0.0039
2026-05-15 2026-03-31 13F KINIKSA PHARMACEUTICALS INTL ORD SHS CL A G52694109 481,023 327,595 23,197 0.0043
2026-02-17 2025-12-31 13F KINIKSA PHARMACEUTICALS INTL ORD SHS CL A G52694109 153,428 141,249 1,159.78 6,325 1,237.21 0.0028
2025-11-14 2025-09-30 13F KINIKSA PHARMACEUTICALS INTL ORD SHS CL A G52694109 12,179 0 0.00 473 40.77 0.0002
2025-08-14 2025-06-30 13F KINIKSA PHARMACEUTICALS INTL ORD SHS CL A G52694109 12,179 0 0.00 337 20.00 0.0002
2025-05-15 2025-03-31 13F KINIKSA PHARMACEUTICALS INTL ORD SHS CL A G52694109 12,179 0 0.00 281 16.67 0.0002
2025-02-14 2024-12-31 13F KINIKSA PHARMACEUTICALS INTL ORD SHS CL A G52694109 12,179 0 0.00 241 -21.05 0.0001
2024-11-14 2024-09-30 13F KINIKSA PHARMACEUTICALS INTL ORD SHS CL A G52694109 12,179 0 0.00 304 33.92 0.0002
2024-08-14 2024-06-30 13F KINIKSA PHARMACEUTICALS INTL ORD SHS CL A G52694109 12,179 12,179 228 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.